Premium
[DT‐02–01]: BRYOSTATIN‐1 IMPROVES COGNITION AND DAILY LIVING TASKS IN MODERATE TO SEVERE ALZHEIMER's DISEASE: PRELIMINARY REPORT OF A PHASE 2 STUDY
Author(s) -
Farlow Martin R.,
Burns Jeffrey M.,
Gorelick Kenneth J.,
Crockford David R.,
Grenier Elaine,
Wilke Susanne,
Cooper Ellen C.,
Alkon Daniel L.
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.08.006
Subject(s) - bryostatin 1 , medicine , placebo , randomization , alzheimer's disease , adverse effect , clinical trial , disease , activator (genetics) , pathology , alternative medicine , receptor
amyloid imaging by PIB PET and/or CSF Ab measures to detect CNS amyloidosis. Participants were given a bolus of C6-leucine label followed by blood sampling over 24 hours. Blood samples were immediately processed to plasma and analyzed in a blinded fashion. Ab isoforms were immunoprecipitated with an anti-Ab antibody and analyzed on a high resolution liquid chromatography mass spectrometer. Results:We found shorter half-life of Ab38 in all participants, and Ab42/40 fractional turnover rate ratios trended towards faster turnover in amyloid positive participants similar to, but of lesser magnitude compared to kinetics measured in CSF. We also found differences in concentrations in amyloid-positive participants. Conclusions:Due to associations of differences in plasma Ab between amyloid positive and negative participants, our findings support the hypothesis that blood Ab interacts with and may be at least partially derived from the CNS. The results also suggest that blood-derived Ab may be useful as a screening test for CNS Ab amyloidosis.